Oxford Biomedica Solutions, LLC is the high-performing, full scope Adeno-Associated Virus (AAV) vector Manufacturing and Innovation joint venture of Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), and Homology Medicines, Inc. (Nasdaq: FIXX) (“Homology”). We offer global pharmaceutical and biotechnology clients innovative manufacturing expertise in AAV and lentiviral-based cell and gene therapies. Oxford Biomedica Solutions LLC provides access to Homology’s innovative and proven end-to-end AAV manufacturing capabilities, and customers also benefit from technical synergies brought in by the Group’s know-how in lentiviral vector manufacturing. This collaborative and complementary vector-based approach has the potential to accelerate our collective mission to improve patients’ lives worldwide.

Biotechnology

Manufacturing

Oxford Biomedica Solutions

Tim Kelly

Ryan Dickerson

Melissa P.

Kelly Quesada

Volker Glidden

Stephen Boyd

Marissa Stanvick

Diane Golebiowski

David Hamilton

Lori Karpes

Amy P.

Patricia Daggett

The Leadership Team at Oxford Biomedica Solutions is responsible for setting the strategic direction, overseeing organizational performance, and ensuring alignment with the company's mission to innovate in AAV and lentiviral-based cell and gene therapies. Comprising the CEO, Senior Vice President, and VP Process Development, this team guides high-level decision-making, fosters collaboration, and drives initiatives that enhance manufacturing capabilities and technical synergies to serve global pharmaceutical and biotechnology clients effectively.

Leadership Team

Research and Development

Director Team

Quality Control and Assurance Team

Leadership Team

About

Team members

Other teams at Oxford Biomedica Solutions

Research and Development

Director Team

Quality Control and Assurance Team